The DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index.
CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance
Open accessAbstract
MM cells express high levels of CD38, while CD38 is expressed at relatively low levels on normal lymphoid and myeloid cells, and in some non-hematopoietic tissues. This expression profile, together with the role of CD38 in adhesion and as ectoenzyme, resulted in the development of CD38 antibodies for the treatment of multiple myeloma (MM). At this moment several CD38 antibodies are at different phases of clinical testing, with daratumumab already approved for various indications both as monotherapy and in combination with standards of care in MM. CD38 antibodies have Fc-dependent immune effector mechanisms, such as complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP). Inhibition of ectoenzymatic function and direct apoptosis induction may also contribute to the efficacy of the antibodies to kill MM cells. The CD38 antibodies also improve host-anti-tumor immunity by the elimination of regulatory T cells, regulatory B cells, and myeloid-derived suppressor cells. Mechanisms of primary and/or acquired resistance include tumor-related factors, such as reduced cell surface expression levels of the target antigen and high levels of complement inhibitors (CD55 and CD59). Differences in frequency or activity of effector cells may also contribute to differences in outcome. Furthermore, the microenvironment protects MM cells to CD38 antibody-induced ADCC by upregulation of anti-apoptotic molecules, such as survivin. Improved understanding of modes of action and mechanisms of resistance has resulted in rationally designed CD38-based combination therapies, which will contribute to further improvement in outcome of MM patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Jiang, H., Acharya, C., An, G., Zhong, M., Feng, X., Wang, L., Dasilva, N., Song, Z., Yang, G., Adrian, F., et al. (2016) · Leukemia · doi:10.1038/leu.2015.240 · Cited by 219 · cited 8×
“by the classical caspase-dependent apoptotic pathway, as well as the lysosomal cell death pathway, which is characterized by lysosomal enlargement, lysosomal membrane permeabilization, and cathepsin hydrolase release (30).”
BackgroundInfluentialRetractedFcγ receptors as regulators of immune responses
Nimmerjahn, F., & Ravetch, J. V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2206 · Cited by 2,947
Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,900
Koyama, S., Akbay, E. A., Li, Y. Y., Herter-Sprie, G. S., Buczkowski, K. A., Richards, W. G., Gandhi, L., Redig, A. J., Rodig, S. J., Asahina, H., et al. (2016) · Nature Communications · doi:10.1038/ncomms10501 · Cited by 1,580
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Palumbo, A., Chanan-Khan, A., Weisel, K., Nooka, A. K., Masszi, T., Beksac, M., Spicka, I., Hungria, V., Munder, M., Mateos, M. V., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606038 · Cited by 1,522
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Dimopoulos, M. A., Oriol, A., Nahi, H., San-Miguel, J., Bahlis, N. J., Usmani, S. Z., Rabin, N., Orlowski, R. Z., Komarnicki, M., Suzuki, K., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607751 · Cited by 1,445 · cited 5×
“The median progression-free survival (PFS) and median overall survival (OS) were 4.0 and 20.1 months, respectively.”
BackgroundInfluentialSelf-citationTargeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
Lokhorst, H. M., Plesner, T., Laubach, J. P., Nahi, H., Gimsing, P., Hansson, M., Minnema, M. C., Lassen, U., Krejcik, J., Palumbo, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506348 · Cited by 1,117 · cited 2×
“In a pooled analysis of 148 patients who received daratumumab treatment as single agent at a dose of 16 mg/kg in the first in human phase 1/2 GEN501 study (41) or in the Sirius study (42), at least partial response (PR) was achieved in 31% of the patients including at least very good partial response (VGPR) in 13.”
BackgroundMethodde Weers, M., Tai, Y.-T., van der Veer, M. S., Bakker, J. M., Vink, T., Jacobs, D. C. H., Oomen, L. A., Peipp, M., Valerius, T., Slootstra, J. W., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003032 · Cited by 1,037
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
Mateos, M.-V., Dimopoulos, M. A., Cavo, M., Suzuki, K., Jakubowiak, A., Knop, S., Doyen, C., Lucio, P., Nagy, Z., Kaplan, P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714678 · Cited by 988
Mössner, E., Brünker, P., Moser, S., Püntener, U., Schmidt, C., Herter, S., Grau, R., Gerdes, C., Nopora, A., van Puijenbroek, E., et al. (2010) · Blood · doi:10.1182/blood-2009-06-225979 · Cited by 981
Krejcik, J., Casneuf, T., Nijhof, I. S., Verbist, B., Bald, J., Plesner, T., Syed, K., Liu, K., van de Donk, N. W. C. J., Weiss, B. M., et al. (2016) · Blood · doi:10.1182/blood-2015-12-687749 · Cited by 954
Self-citationDamiano, J. S., Cress, A. E., Hazlehurst, L. A., Shtil, A. A., & Dalton, W. S. (1999) · Blood · doi:10.1182/blood.v93.5.1658 · Cited by 901
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Moreau, P., San Miguel, J., Sonneveld, P., Mateos, M. V., Zamagni, E., Avet-Loiseau, H., Hajek, R., Dimopoulos, M. A., Ludwig, H., Einsele, H., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx096 · Cited by 877
Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology
Malavasi, F., Deaglio, S., Funaro, A., Ferrero, E., Horenstein, A. L., Ortolan, E., Vaisitti, T., & Aydin, S. (2008) · Physiological Reviews · doi:10.1152/physrev.00035.2007 · Cited by 862
Lonial, S., Weiss, B. M., Usmani, S. Z., Singhal, S., Chari, A., Bahlis, N. J., Belch, A., Krishnan, A., Vescio, R. A., Mateos, M. V., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01120-4 · Cited by 854
Self-citationTargeting immunosuppressive adenosine in cancer
Vijayan, D., Young, A., Teng, M. W. L., & Smyth, M. J. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.86 · Cited by 840
Complement Is Activated by IgG Hexamers Assembled at the Cell Surface
Diebolder, C. A., Beurskens, F. J., de Jong, R. N., Koning, R. I., Strumane, K., Lindorfer, M. A., Voorhorst, M., Ugurlar, D., Rosati, S., Heck, A. J. R., et al. (2014) · Science · doi:10.1126/science.1248943 · Cited by 796
Koene, H. R., Kleijer, M., Algra, J., Roos, D., E.G.Kr. von dem Borne, A., & de Haas, M. (1997) · Blood · doi:10.1182/blood.v90.3.1109 · Cited by 794
De-novo and acquired resistance to immune checkpoint targeting
Syn, N. L., Teng, M. W. L., Mok, T. S. K., & Soo, R. A. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30607-1 · Cited by 662
Golay, J., Zaffaroni, L., Vaccari, T., Lazzari, M., Borleri, G.-M., Bernasconi, S., Tedesco, F., Rambaldi, A., & Introna, M. (2000) · Blood · doi:10.1182/blood.v95.12.3900 · Cited by 604
The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity
Park, S., Jiang, Z., Mortenson, E. D., Deng, L., Radkevich-Brown, O., Yang, X., Sattar, H., Wang, Y., Brown, N. K., Greene, M., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.06.014 · Cited by 577 · cited 1×
“This has been demonstrated for several therapeutic antibodies (24), but additional investigations are required to analyze to what extent FcγR-mediated enhancement of antigen presentation contributes to the anti-MM activity of CD38-targeting antibodies.”
BackgroundOverdijk, M. B., Verploegen, S., Bögels, M., van Egmond, M., van Bueren, J. J. L., Mutis, T., Groen, R. W., Breij, E., Martens, A. C., Bleeker, W. K., et al. (2015) · mAbs · doi:10.1080/19420862.2015.1007813 · Cited by 521
CD38 antibodies in multiple myeloma: back to the future
van de Donk, N. W. C. J., Richardson, P. G., & Malavasi, F. (2018) · Blood · doi:10.1182/blood-2017-06-740944 · Cited by 493
Self-citationZhang, W., Gordon, M., Schultheis, A. M., Yang, D. Y., Nagashima, F., Azuma, M., Chang, H.-M., Borucka, E., Lurje, G., Sherrod, A. E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.8021 · Cited by 482
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma
Chari, A., Suvannasankha, A., Fay, J. W., Arnulf, B., Kaufman, J. L., Ifthikharuddin, J. J., Weiss, B. M., Krishnan, A., Lentzsch, S., Comenzo, R., et al. (2017) · Blood · doi:10.1182/blood-2017-05-785246 · Cited by 443
Golay, J., Lazzari, M., Facchinetti, V., Bernasconi, S., Borleri, G., Barbui, T., Rambaldi, A., & Introna, M. (2001) · Blood · doi:10.1182/blood.v98.12.3383 · Cited by 428
Mellor, J. D., Brown, M. P., Irving, H. R., Zalcberg, J. R., & Dobrovic, A. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-1 · Cited by 415
Romagné, F., André, P., Spee, P., Zahn, S., Anfossi, N., Gauthier, L., Capanni, M., Ruggeri, L., Benson, D. M., Blaser, B. W., et al. (2009) · Blood · doi:10.1182/blood-2009-02-206532 · Cited by 408
Usmani, S. Z., Weiss, B. M., Plesner, T., Bahlis, N. J., Belch, A., Lonial, S., Lokhorst, H. M., Voorhees, P. M., Richardson, P. G., Chari, A., et al. (2016) · Blood · doi:10.1182/blood-2016-03-705210 · Cited by 407
Self-citationNijhof, I. S., Casneuf, T., van Velzen, J., van Kessel, B., Axel, A. E., Syed, K., Groen, R. W. J., van Duin, M., Sonneveld, P., Minnema, M. C., et al. (2016) · Blood · doi:10.1182/blood-2016-03-703439 · Cited by 393
Self-citationMonoclonal antibodies targeting CD 38 in hematological malignancies and beyond
van de Donk, N. W. C. J., Janmaat, M. L., Mutis, T., Lammerts van Bueren, J. J., Ahmadi, T., Sasser, A. K., Lokhorst, H. M., & Parren, P. W. H. I. (2016) · Immunological Reviews · doi:10.1111/imr.12389 · Cited by 353
Self-citationDeckert, J., Wetzel, M.-C., Bartle, L. M., Skaletskaya, A., Goldmacher, V. S., Vallée, F., Zhou-Liu, Q., Ferrari, P., Pouzieux, S., Lahoute, C., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0695 · Cited by 333
The coordination of signaling during Fc receptor-mediated phagocytosis
Swanson, J. A., & Hoppe, A. D. (2004) · Journal of Leukocyte Biology · doi:10.1189/jlb.0804439 · Cited by 331
Bengsch, B., Ohtani, T., Khan, O., Setty, M., Manne, S., O’Brien, S., Gherardini, P. F., Herati, R. S., Huang, A. C., Chang, K.-M., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.04.026 · Cited by 318
Overdijk, M. B., Jansen, J. H. M., Nederend, M., Lammerts van Bueren, J. J., Groen, R. W. J., Parren, P. W. H. I., Leusen, J. H. W., & Boross, P. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1501351 · Cited by 297
Human CD38: a (r)evolutionary story of enzymes and receptors
Deaglio, S., Mehta, K., & Malavasi, F. (2001) · Leukemia Research · doi:10.1016/s0145-2126(00)00093-x · Cited by 285
Shushakova, N., Skokowa, J., Schulman, J., Baumann, U., Zwirner, J., Schmidt, R. E., & Gessner, J. E. (2002) · Journal of Clinical Investigation · doi:10.1172/jci16577 · Cited by 284
CD38-NAD+Axis Regulates Immunotherapeutic Anti-Tumor T Cell Response
Chatterjee, S., Daenthanasanmak, A., Chakraborty, P., Wyatt, M. W., Dhar, P., Selvam, S. P., Fu, J., Zhang, J., Nguyen, H., Kang, I., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2017.10.006 · Cited by 270
Nijhof, I. S., Groen, R. W. J., Lokhorst, H. M., van Kessel, B., Bloem, A. C., van Velzen, J., de Jong-Korlaar, R., Yuan, H., Noort, W. A., Klein, S. K., et al. (2015) · Leukemia · doi:10.1038/leu.2015.123 · Cited by 267
Self-citationFeng, X., Zhang, L., Acharya, C., An, G., Wen, K., Qiu, L., Munshi, N. C., Tai, Y.-T., & Anderson, K. C. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3192 · Cited by 252
Czuczman, M. S., Olejniczak, S., Gowda, A., Kotowski, A., Binder, A., Kaur, H., Knight, J., Starostik, P., Deans, J., & Hernandez-Ilizaliturri, F. J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1254 · Cited by 232
Immune complex–mediated antigen presentation induces tumor immunity
Rafiq, K., Bergtold, A., & Clynes, R. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215640 · Cited by 232
CD16 is indispensable for antibody-dependent cellular cytotoxicity by human monocytes
Yeap, W. H., Wong, K. L., Shimasaki, N., Teo, E. C. Y., Quek, J. K. S., Yong, H. X., Diong, C. P., Bertoletti, A., Linn, Y. C., & Wong, S. C. (2016) · Scientific Reports · doi:10.1038/srep34310 · Cited by 229
Casneuf, T., Xu, X. S., Adams, H. C., Axel, A. E., Chiu, C., Khan, I., Ahmadi, T., Yan, X., Lonial, S., Plesner, T., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017006866 · Cited by 229
Self-citationPreclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia
Bride, K. L., Vincent, T. L., Im, S.-Y., Aplenc, R., Barrett, D. M., Carroll, W. L., Carson, R., Dai, Y., Devidas, M., Dunsmore, K. P., et al. (2018) · Blood · doi:10.1182/blood-2017-07-794214 · Cited by 229
Kaufman, G. P., Schrier, S. L., Lafayette, R. A., Arai, S., Witteles, R. M., & Liedtke, M. (2017) · Blood · doi:10.1182/blood-2017-01-763599 · Cited by 225
Lammerts van Bueren, J., Jakobs, D., Kaldenhoven, N., Roza, M., Hiddingh, S., Meesters, J., Voorhorst, M., Gresnigt, E., Wiegman, L., Ortiz Buijsse, A., et al. (2014) · Blood · doi:10.1182/blood.v124.21.3474.3474 · Cited by 222
van der Veer, M. S., de Weers, M., van Kessel, B., Bakker, J. M., Wittebol, S., Parren, P. W. H. I., Lokhorst, H. M., & Mutis, T. (2011) · Haematologica · doi:10.3324/haematol.2010.030759 · Cited by 218
Benson, D. M., Bakan, C. E., Zhang, S., Collins, S. M., Liang, J., Srivastava, S., Hofmeister, C. C., Efebera, Y., Andre, P., Romagne, F., et al. (2011) · Blood · doi:10.1182/blood-2011-06-360255 · Cited by 208
van de Donk, N. W. C. J., Moreau, P., Plesner, T., Palumbo, A., Gay, F., Laubach, J. P., Malavasi, F., Avet-Loiseau, H., Mateos, M.-V., Sonneveld, P., et al. (2016) · Blood · doi:10.1182/blood-2015-10-646810 · Cited by 203
Self-citationJazirehi, A. R., Huerta‐Yépez, S., Cheng, G., & Bonavida, B. (2005) · Cancer Research · doi:10.1158/0008-5472.264.65.1 · Cited by 192
Hatano, K., Kikuchi, J., Takatoku, M., Shimizu, R., Wada, T., Ueda, M., Nobuyoshi, M., Oh, I., Sato, K., Suzuki, T., et al. (2009) · Oncogene · doi:10.1038/onc.2008.385 · Cited by 191
Phagocytosis Dynamics Depends on Target Shape
Paul, D., Achouri, S., Yoon, Y.-Z., Herre, J., Bryant, C. E., & Cicuta, P. (2013) · Biophysical Journal · doi:10.1016/j.bpj.2013.07.036 · Cited by 185
Jazirehi, A. R., Huerta‐Yépez, S., Cheng, G., & Bonavida, B. (2005) · PubMed · Cited by 176
Krejcik, J., Frerichs, K. A., Nijhof, I. S., van Kessel, B., van Velzen, J. F., Bloem, A. C., Broekmans, M. E. C., Zweegman, S., van Meerloo, J., Musters, R. J. P., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2027 · Cited by 176
Self-citationFc receptors and their interaction with complement in autoimmunity
Schmidt, R. E., & Gessner, J. E. (2005) · Immunology Letters · doi:10.1016/j.imlet.2005.06.022 · Cited by 174
Martin, T., Baz, R., Benson, D. M., Lendvai, N., Wolf, J., Munster, P., Lesokhin, A. M., Wack, C., Charpentier, E., Campana, F., et al. (2017) · Blood · doi:10.1182/blood-2016-09-740787 · Cited by 166
Adams, H. C., Stevenaert, F., Krejcik, J., Van der Borght, K., Smets, T., Bald, J., Abraham, Y., Ceulemans, H., Chiu, C., Vanhoof, G., et al. (2019) · Cytometry Part A · doi:10.1002/cyto.a.23693 · Cited by 163
Self-citationNijhof, I. S., Groen, R. W. J., Noort, W. A., van Kessel, B., de Jong-Korlaar, R., Bakker, J., van Bueren, J. J. L., Parren, P. W. H. I., Lokhorst, H. M., van de Donk, N. W. C. J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1813 · Cited by 151
Self-citationComplement in therapy and disease
Melis, J. P. M., Strumane, K., Ruuls, S. R., Beurskens, F. J. M., Schuurman, J., & Parren, P. W. H. I. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.01.028 · Cited by 149
Morandi, F., Horenstein, A. L., Chillemi, A., Quarona, V., Chiesa, S., Imperatori, A. S., Zanellato, S., Mortara, L., Gattorno, M., Pistoia, V., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500591 · Cited by 140
Wang, Y., Zhang, Y., Hughes, T. L., Zhang, J., Caligiuri, M. A., Benson, D. M., & Yu, J. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3117 · Cited by 133
Bjorklund, C. C., Baladandayuthapani, V, Lin, H. Y., Jones, R. J., Kuiatse, I., Wang, H., Yang, J., Shah, J. J., Thomas, S. K., Wang, M., et al. (2014) · Leukemia · doi:10.1038/leu.2013.174 · Cited by 131
Drach, J. W., McQueen, T. J., Engel, H., Andreeff, M., Robertson, K. A., Collins, S. J., Malavasi, F., & Mehta, K. (1994) · PubMed · Cited by 129
Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer
Meyer, S., Leusen, J. H. W., & Boross, P. (2014) · mAbs · doi:10.4161/mabs.29670 · Cited by 127
Hao, M., Zhang, L., An, G., Meng, H., Han, Y.-J., Xie, Z., Xu, Y., Li, C., Yu, Z., Chang, H. H., et al. (2011) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2011.576791 · Cited by 123
CD38/CD19: a lipid raft–dependent signaling complex in human B cells
Deaglio, S., Vaisitti, T., Billington, R. A., Bergui, L., Omedè, P., Genazzani, A. A., & Malavasi, F. (2007) · Blood · doi:10.1182/blood-2006-12-061812 · Cited by 118
NAD+-Metabolizing Ectoenzymes in Remodeling Tumor–Host Interactions: The Human Myeloma Model
Horenstein, A. L., Chillemi, A., Quarona, V., Zito, A., Roato, I., Morandi, F., Marimpietri, D., Bolzoni, M., Toscani, D., Oldham, R. J., et al. (2015) · Cells · doi:10.3390/cells4030520 · Cited by 116
Molecular Mechanism of Human CD38 Gene Expression by Retinoic Acid
Kishimoto, H., Hoshino, S.-I., Ohori, M., Kontani, K., Nishina, H., Suzawa, M., Kato, S., & Katada, T. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.25.15429 · Cited by 114
Nijhof, I. S., van Bueren, J. J. L., van Kessel, B., André, P., Morel, Y., Lokhorst, H. M., van de Donk, N. W. C. J., Parren, P. W. H. I., & Mutis, T. (2014) · Haematologica · doi:10.3324/haematol.2014.117531 · Cited by 114
Landgren, C. O., Chari, A., Cohen, Y. C., Spencer, A., Voorhees, P., Estell, J. A., Sandhu, I., Jenner, M. W., Williams, C., Cavo, M., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0718-z · Cited by 102
Immunomodulatory effects of CD38-targeting antibodies
van de Donk, N. W. C. J. (2018) · Immunology Letters · doi:10.1016/j.imlet.2018.04.005 · Cited by 101
Targeting CD38 in Refractory Extranodal Natural Killer Cell–T-Cell Lymphoma
Hari, P., Raj, R. V., & Olteanu, H. (2016) · New England Journal of Medicine · doi:10.1056/nejmc1605684 · Cited by 100
Horenstein, A. L., Quarona, V., Toscani, D., Costa, F., Chillemi, A., Pistoia, V., Giuliani, N., & Malavasi, F. (2016) · Molecular Medicine · doi:10.2119/molmed.2016.00198 · Cited by 100
van der Veer, M. S., de Weers, M., van Kessel, B., Bakker, J. M., Wittebol, S. H., Parren, P. W. H. I., Lokhorst, H. M., & Mutis, T. (2011) · Blood Cancer Journal · doi:10.1038/bcj.2011.42 · Cited by 99
Taylor, R. P., & Lindorfer, M. A. (2016) · Seminars in Immunology · doi:10.1016/j.smim.2016.03.003 · Cited by 98
Panobinostat induces CD38 upregulation and augments the antimyeloma efficacy of daratumumab
García‐Guerrero, E., Gogishvili, T., Danhof, S., Schreder, M., Pallaud, C., Pérez‐Simón, J. A., Einsele, H., & Hudecek, M. (2017) · Blood · doi:10.1182/blood-2017-03-770776 · Cited by 96
Nooka, A. K., Joseph, N. S., Kaufman, J. L., Heffner, L. T., Gupta, V. A., Gleason, C. L., Boise, L., & Lonial, S. (2019) · Cancer · doi:10.1002/cncr.32178 · Cited by 96
Human CD59 Inhibitor Sensitizes Rituximab-Resistant Lymphoma Cells to Complement-Mediated Cytolysis
Hu, W., Ge, X., You, T., Xu, T., Zhang, J., Wu, G., Peng, Z., Chorev, M., Aktas, B. H., Halperin, J. A., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3016 · Cited by 91
Macor, P., Secco, E., Mezzaroba, N., Zorzet, S., Durigutto, P., Gaiotto, T., Maso, L. D., Biffi, S., Garrovo, C., Capolla, S., et al. (2014) · Leukemia · doi:10.1038/leu.2014.185 · Cited by 84
Sher, T., Fenton, B., Akhtar, A., & Gertz, M. A. (2016) · Blood · doi:10.1182/blood-2016-06-722496 · Cited by 84
Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma
van de Donk, N. W. C. J., Kamps, S., Mutis, T., & Lokhorst, H. M. (2011) · Leukemia · doi:10.1038/leu.2011.214 · Cited by 83
Treatment of relapsed and refractory multiple myeloma in the era of novel agents
van de Donk, N. W. C. J., Lokhorst, H. M., Dimopoulos, M. A., Cavo, M., Morgan, G. J., Einsele, H., Kropff, M. H., Schey, S., Avet‐Loiseau, H., Ludwig, H., et al. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.08.008 · Cited by 81
Braza, M. S., Klein, B., Fiol, G., & Rossi, J. (2010) · Haematologica · doi:10.3324/haematol.2010.029520 · Cited by 75
de Haart, S. J., van de Donk, N. W. C. J., Minnema, M. C., Huang, J. H. Y., Aarts‐Riemens, T., Bovenschen, N., Yuan, H., Groen, R. W. J., McMillin, D. W., Jakubíková, J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3676 · Cited by 73
Daratumumab for the Treatment of Multiple Myeloma
Plesner, T., & Krejcik, J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01228 · Cited by 71
van Bommel, P. E., He, Y. Z., Schepel, I., Hendriks, M. A. J. M., Wiersma, V. R., van Ginkel, R. J., van Meerten, T., Ammatuna, E., Huls, G. A., Samplonius, D. F., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1386361 · Cited by 70
Chillemi, A., Zaccarello, G., Quarona, V., Ferracin, M., Ghimenti, C., Massaia, M., Horenstein, A. L., & Malavasi, F. (2013) · Molecular Medicine · doi:10.2119/molmed.2013.00009 · Cited by 63
Effect of FCGR2A and FCGR3A variants on CLL outcome
Dornan, D., Spleiss, O., Yeh, R.-F., Duchâteau-Nguyen, G., Dufour, A. M., Zhi, J., Robak, T., Si, M., Dmoszyńska, A., Solal‐Céligny, P., et al. (2010) · Blood · doi:10.1182/blood-2010-03-272765 · Cited by 61
Gavriatopoulou, M., Kastritis, E., Ntanasis‐Stathopoulos, I., Fotiou, D., Ρούσσου, Μ., Migkou, M., Ziogas, D. C., Kanellias, N., Terpos, E., & Dimopoulos, M. A. (2017) · Blood · doi:10.1182/blood-2017-10-809293 · Cited by 60
Busch, L., Mougiakakos, D., Büttner-Herold, M. J., Müller, M. J., Volmer, D. A., Bach, C., Fabri, M., Bittenbring, J. T., Neumann, F., Boxhammer, R., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0114-0 · Cited by 46
Ge, X., Wu, L., Hu, W., Fernandes, S. M., Wang, C., Li, X., Brown, J. R., & Qin, X. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0647 · Cited by 44
de Haart, S. J., Holthof, L. C., Noort, W. A., Minnema, M. C., Emmelot, M. E., Aarts‐Riemens, T., Doshi, P. D., Sasser, K., Yuan, H., de Bruijn, J. D., et al. (2016) · Haematologica · doi:10.3324/haematol.2015.139667 · Cited by 44
Raab, M. S., Chatterjee, M., Goldschmidt, H., Agis, H., Blau, I. W., Einsele, H., Engelhardt, M. M., Ferstl, B., Gramatzki, M., Röllig, C., et al. (2016) · Blood · doi:10.1182/blood.v128.22.1152.1152 · Cited by 39
Richter, J. R., Martin, T. G., Vij, R., Cole, C. E., Atanackovic, D., Zonder, J. A., Kaufman, J. L., Mikhael, J. R., Bensinger, W., Dimopoulos, M. A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.8005 · Cited by 36
Martin, T. G., Richter, J. R., Vij, R., Cole, C. E., Atanackovic, D., Zonder, J. A., Kaufman, J. L., Bensinger, W., Dimopoulos, M. A., Miguel, J. F. S., et al. (2015) · Blood · doi:10.1182/blood.v126.23.509.509 · Cited by 34
Martin, T. G., Strickland, S. A., Glenn, M. J., Zheng, W., Daskalakis, N., & Mikhael, J. R. (2013) · Blood · doi:10.1182/blood.v122.21.284.284 · Cited by 33
Raab, M. S., Goldschmidt, H., Agis, H., Blau, I. W., Einsele, H., Engelhardt, M. M., Ferstl, B., Gramatzki, M., Röllig, C., Weisel, K. C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.8574 · Cited by 29
Rashidi, A., & Fisher, S. I. (2016) · Blood · doi:10.1182/blood-2016-06-720862 · Cited by 28
Phase Ib Study of Isatuximab and Carfilzomib in Relapse and Refractory Multiple Myeloma
Martin, T. G., Mannis, G. N., Chari, A., Münster, P. N., Campana, F., Hui, A., & Wolf, J. L. (2016) · Blood · doi:10.1182/blood.v128.22.2111.2111 · Cited by 28
Nooka, A. K., Joseph, N. S., Boise, L. H., Gleason, C. L., Kaufman, J. L., & Lonial, S. (2016) · Blood · doi:10.1182/blood.v128.22.492.492 · Cited by 27
van de Donk, N. W. C. J., Casneuf, T., Cara, A. D., Parren, P. W. H. I., Zweegman, S., van Kessel, B., Lokhorst, H. M., Usmani, S. Z., Lonial, S., Richardson, P. G. G., et al. (2018) · British Journal of Haematology · doi:10.1111/bjh.15122 · Cited by 24
Self-citationAnti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy
Zamagni, E., Tacchetti, P., Pantani, L., & Cavo, M. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1456331 · Cited by 22
Weisel, K. C., Miguel, J. F. S., Cook, G., Leiba, M., Suzuki, K., Kumar, S. K., Cavo, M., Avet‐Loiseau, H., Quach, H., Hungria, V., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.8006 · Cited by 19
Usmani, S. Z., Khan, I., Chiu, C. W., Foureau, D., Druhan, L. J., Rigby, K., Casneuf, T., & Sasser, A. K. (2018) · Experimental Hematology and Oncology · doi:10.1186/s40164-018-0096-7 · Cited by 19
Self-citationChu, S. Y., Miranda, Y., Phung, S., Chen, H., Rashid, R., Endo, N. A., Chan, E. W., Pong, E., Bonzon, C., Muchhal, U. S., et al. (2014) · Blood · doi:10.1182/blood.v124.21.4727.4727 · Cited by 18
Editorial: CD38 and retinoids: a step toward a cure
Malavasi, F. (2011) · Journal of Leukocyte Biology · doi:10.1189/jlb.0211069 · Cited by 16
An, G., Jiang, H., Acharya, C., Zhong, M. Y., Cai, T., Yang, G., Song, Z., Theilhaber, J., Adrián, F., Tai, Y., et al. (2014) · Blood · doi:10.1182/blood.v124.21.4729.4729 · Cited by 16
Chen, L., Byers, L. A., Ullrich, S. E., Wistuba, I. I., Qin, F. X.-F., & Gibbons, D. L. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.7_suppl.79 · Cited by 16
Neri, P. E., Maity, R., Tagoug, I., Duggan, P. R., McCulloch, S., Jimenez-Zepeda, V. H., Tay, J., Boise, L., Thakurta, A., & Bahlis, N. J. (2017) · Blood · doi:10.1182/blood.v130.suppl_1.123.123 · Cited by 16
Rigalou, A., Ryan, A. E., Natoni, A., Chiu, C., Sasser, K., & O'Dwyer, M. E. (2016) · Blood · doi:10.1182/blood.v128.22.2101.2101 · Cited by 15
Daratumumab Efficiently Targets NK/T Cell Lymphoma with High CD38 Expression
Mustafa, N. B., Nee, H. F. A., Lee, X. T. J., Jin, W. J., Yu, Y., Chen, Y. P., Yang, J., & Chng, W. J. (2017) · Blood · doi:10.1182/blood.v130.suppl_1.2814.2814 · Cited by 15
van de Donk, N. W. C. J., Adams, H., Vanhoof, G., Krejcik, J., der Borght, K. V., Casneuf, T., Smets, T., Axel, A. E., Abraham, Y., Ceulmans, H., et al. (2017) · Blood · doi:10.1182/blood.v130.suppl_1.3124.3124 · Cited by 14
Self-citationBezman, N., Kinder, M., Jhatakia, A., Mattson, B. K., Pizutti, D., Thompson, E. W., Capaldi, D., Mendonça, M., Anandam, A., Dhar, G., et al. (2018) · Cancer Research · doi:10.1158/1538-7445.am2018-1727 · Cited by 13
Marra, J. D., Du, J., Hwang, J. J., Wolf, J. L., Martin, T. G., & Venstrom, J. M. (2014) · Blood · doi:10.1182/blood.v124.21.2126.2126 · Cited by 12
Adams, H., Stevenaert, F., Krejcik, J., der Borght, K. V., Casneuf, T., Smets, T., Bald, J., Abraham, Y., Ceulemans, H., Vanhoof, G., et al. (2016) · Blood · doi:10.1182/blood.v128.22.4521.4521 · Cited by 11
Self-citation
Cited by
Translating gammadelta (γδ) T cells and their receptors into cancer cell therapies
Sebestyen, Z., Prinz, I., Déchanet-Merville, J., Silva-Santos, B., & Kuball, J. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0038-z · Cited by 425
CD38: An Immunomodulatory Molecule in Inflammation and Autoimmunity
Piedra-Quintero, Z. L., Wilson, Z., Nava, P., & Guerau-de-Arellano, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.597959 · Cited by 332
Cohen, Y. C., Zada, M., Wang, S.-Y., Bornstein, C., David, E., Moshe, A., Li, B., Shlomi-Loubaton, S., Gatt, M. E., Gur, C., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01232-w · Cited by 235
Bjorklund, C. C., Kang, J., Amatangelo, M., Polonskaia, A., Katz, M., Chiu, H., Couto, S., Wang, M., Ren, Y., Ortiz, M., et al. (2020) · Leukemia · doi:10.1038/s41375-019-0620-8 · Cited by 205
Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab
Martin, T. G., Corzo, K., Chiron, M., van de Velde, H., Abbadessa, G., Campana, F., Solanki, M., Meng, R., Lee, H., Wiederschain, D., et al. (2019) · Cells · doi:10.3390/cells8121522 · Cited by 166
Metadata
- Authors
- van de Donk, N. W. C. J., & Usmani, S. Z.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2018-09-20
- Volume
- 9
- Pages
- 2134-2134
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2891882983
- Cited by
- 354
- References
- 116
- FWCI
- 20.21
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.